SEC Tracker
Get the app

BeiGene ONC

BeiGene FY 2024: revenue $3.8B, up 55%; diluted EPS −$0.47

Form
10-K/A
Filed
Period
Importance
Routine
Document
10-K/A

Key figures from this report

These are the numbers BeiGene reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$3.8B+55% from $2.5B in FY 202310-K income statement, on EDGAR
  2. Net income−$644.8MAgainst −$881.7M in FY 202310-K income statement, on EDGAR
  3. Diluted EPS−$0.47Against −$0.65 in FY 202310-K income statement, on EDGAR
  4. Cash and cash equivalents$2.6B−17% from $3.2B in FY 202310-K balance sheet, on EDGAR
  5. Cash from operations−$140.6MAgainst −$1.2B in FY 202310-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when BeiGene files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Teva Pharmaceutical Industries TEVA public float $18.2B, Jun 30, 2025
  2. Biogen BIIB public float $18.4B, Jun 30, 2025
  3. United Therapeutics UTHR public float $11.2B, Jun 30, 2025
  4. INSMED INSM public float $21.1B, Jun 30, 2025
  5. Roivant Sciences ROIV public float $9.8B, Sep 30, 2025